NO20020578D0 - Substituerte pyrrolidin-2,3,4-trion-3-oskimderivater som er nyttige som NMDA-reseptorantagonister - Google Patents

Substituerte pyrrolidin-2,3,4-trion-3-oskimderivater som er nyttige som NMDA-reseptorantagonister

Info

Publication number
NO20020578D0
NO20020578D0 NO20020578A NO20020578A NO20020578D0 NO 20020578 D0 NO20020578 D0 NO 20020578D0 NO 20020578 A NO20020578 A NO 20020578A NO 20020578 A NO20020578 A NO 20020578A NO 20020578 D0 NO20020578 D0 NO 20020578D0
Authority
NO
Norway
Prior art keywords
oskim
trione
receptor antagonists
nmda receptor
derivatives useful
Prior art date
Application number
NO20020578A
Other languages
English (en)
Other versions
NO20020578L (no
Inventor
Michael Przewosny
Hans-Dietrich Stachel
Hermann Poschenrieder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of NO20020578D0 publication Critical patent/NO20020578D0/no
Publication of NO20020578L publication Critical patent/NO20020578L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
NO20020578A 1999-08-06 2002-02-05 Substituerte pyrrolidin-2,3,4-trion-3-oksimderivater som er nyttige som NMDA-reseptorantagonister NO20020578L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19936521A DE19936521A1 (de) 1999-08-06 1999-08-06 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
PCT/EP2000/007101 WO2001010831A1 (de) 1999-08-06 2000-07-25 Substituierte pyrrolidin-2,3,4-trion-3-oxim-derivate wirksam als nmda-rezeptor antagonistem

Publications (2)

Publication Number Publication Date
NO20020578D0 true NO20020578D0 (no) 2002-02-05
NO20020578L NO20020578L (no) 2002-03-25

Family

ID=7917036

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020578A NO20020578L (no) 1999-08-06 2002-02-05 Substituerte pyrrolidin-2,3,4-trion-3-oksimderivater som er nyttige som NMDA-reseptorantagonister

Country Status (25)

Country Link
US (1) US6716872B2 (no)
EP (1) EP1200400B1 (no)
JP (1) JP2003506436A (no)
KR (1) KR20020025215A (no)
CN (1) CN1378531A (no)
AR (1) AR030678A1 (no)
AT (1) ATE277901T1 (no)
AU (1) AU779187B2 (no)
BR (1) BR0013313A (no)
CA (1) CA2380973A1 (no)
CO (1) CO5190692A1 (no)
DE (2) DE19936521A1 (no)
ES (1) ES2226876T3 (no)
HK (1) HK1046404A1 (no)
HU (1) HUP0202433A3 (no)
IL (1) IL147978A0 (no)
MX (1) MXPA02001215A (no)
NO (1) NO20020578L (no)
NZ (1) NZ516905A (no)
PE (1) PE20010381A1 (no)
PL (1) PL353875A1 (no)
PT (1) PT1200400E (no)
SK (1) SK1692002A3 (no)
WO (1) WO2001010831A1 (no)
ZA (1) ZA200201789B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349888T1 (de) * 2002-02-13 2007-01-15 Univ Tokyo Agriculture & Technology Tlo Co Ltd Automatisches tierbewegungsbeobachtungsverfahren und vorrichtung dafür sowie bewegungsquantisierungsvorrichtung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832790A (en) * 1954-09-28 1958-04-29 Du Pont 4-negative functionally substituted 2, 3, 5-trichalcogenpyrrolidines, their salts, and methods for preparing them
DE4317651A1 (de) * 1993-05-27 1994-12-01 Hoechst Ag Substituierte Bernsteinsäureimide
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel

Also Published As

Publication number Publication date
ES2226876T3 (es) 2005-04-01
EP1200400A1 (de) 2002-05-02
NO20020578L (no) 2002-03-25
MXPA02001215A (es) 2002-07-02
BR0013313A (pt) 2002-04-16
DE19936521A1 (de) 2001-02-15
PL353875A1 (en) 2003-12-01
CA2380973A1 (en) 2001-02-15
IL147978A0 (en) 2002-09-12
JP2003506436A (ja) 2003-02-18
HUP0202433A2 (hu) 2002-12-28
AU779187B2 (en) 2005-01-13
HUP0202433A3 (en) 2003-06-30
NZ516905A (en) 2004-07-30
ZA200201789B (en) 2003-06-25
DE50008020D1 (de) 2004-11-04
SK1692002A3 (en) 2002-07-02
WO2001010831A1 (de) 2001-02-15
ATE277901T1 (de) 2004-10-15
AR030678A1 (es) 2003-09-03
KR20020025215A (ko) 2002-04-03
PE20010381A1 (es) 2001-05-05
CN1378531A (zh) 2002-11-06
US6716872B2 (en) 2004-04-06
CO5190692A1 (es) 2002-08-29
PT1200400E (pt) 2005-02-28
HK1046404A1 (zh) 2003-01-10
US20030027852A1 (en) 2003-02-06
AU5986800A (en) 2001-03-05
EP1200400B1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
NO985225L (no) Indolderivater nyttige som endotelinreseptorantagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
NO20023485D0 (no) 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20032678L (no) NMDA reseptor agonist farmasöytiske sammensetninger
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20002036L (no) Cyklopentenderivater anvendbare som antagonister for motilinreseptoren
NO20020578L (no) Substituerte pyrrolidin-2,3,4-trion-3-oksimderivater som er nyttige som NMDA-reseptorantagonister
AU2001261487A1 (en) Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
DK0912556T3 (da) Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister
HK1042699A1 (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists.
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
DK1200400T3 (da) Substituerede pyrrolidin-2,3,4-trion derivater, der er anvendelse som NMDA-receptorantagonister
SI1200400T1 (en) Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
DK1207159T3 (da) Heteroaromatiske derivater som dopamin-D4-receptorantagonister
DK1347760T3 (da) Farmaceutiske kompositioner med NMDA receptor agonister
NO963775D0 (no) Indol-derivater som CCK-reseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application